AUG 14, 2018 11:30 PM PDT

Single Antiplatelet Drug Reduces Risk of Blood Clots

WRITTEN BY: Nouran Amin

Image Retrieved From Unsplash, www.unsplash.com

According to the current treatment protocol, patients that undergo minimally invasive aortic heart valve replacements will likely receive two antiplatelet drugs that reduce the likelihood of developing dangerous blood clots. Now, a new meta-analysis study by Loyola Medicine has found that administering just one antiplatelet drug is sufficient enough to reduce the risk of life-threatening bleeding in comparison to two of these drugs. The study was published in the July issue of the American Journal of Cardiology and led by Verghese Mathew, MD, a renowned interventional cardiologist and chair of Loyola's division of cardiology.

The aortic valve is responsible for regulating blood flow from the hearts main pumping chamber, the left ventricle, to the body’s largest artery, the aorta. Aortic stenosis is caused by the narrowing of the aortic valve, which can cause chest pain and fatigue to many affected individuals, and severe symptoms can lead to heart failure and death. To replace a diseased aortic valve usually required an open heart surgery. But in 2011, a minimally invasive technique was developed to implant an artificial valve with a catheter. The technique is known as transcatheter aortic valve replacement (TAVR) where the catheter is inserted into an artery in the groin and is led up to the heat where the valve is placed.

Watch Video Below To Understand TAVR:

 

TAVR is commercially available in the United States. After administering TAVR, patients usually take two antiplatelets known as ‘dual-antiplatelet therapy’ to reduce the risk of developing blood clots. Commonly used antiplatelet drugs are aspirin and clopidogrel (Plavix). However, the treatments vary depending on the cardiologist assigned. Some providers prescribe their patients just one antiplatelet called the ‘mono-antiplatelet therapy’ usually when the patients have an increased concern of bleeding from the dual-antiplatelet therapy. However, in the study, Dr. Mathew and team analyzed the results of eight studies that compared mono-antiplatelet therapy to the use of dual-antiplatelet therapy. The studies examined 2,439 patients in total and in four of these studies, patients were deployed the Sapien aortic valve and in two studies, they received the CoreValve device. Finally, in two of these studies, both valves were administered. During 30 days, patients given two antiplatelet agents were 2.06 times more likely to die, 2.04 times more likely to develop life-threatening bleeding and 2.15 times more likely to undergo major vascular complications. "These data suggest a safety concern with dual-antiplatelet therapy and underscore the need for a large randomized trial to definitely address this question," Dr. Mathew and colleagues wrote.

Source: Loyola University Health System

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 23, 2019
Drug Discovery & Development
NOV 23, 2019
Drug Seeks To Target Treatment-Resistant Epilepsy
Ever imagined a world where you cannot shower alone, drive by yourself, and even go to work in fear of having the next seizure that can incapacitate you? U...
DEC 22, 2019
Genetics & Genomics
DEC 22, 2019
New Gene Therapy Uses Exosomes to Reverse Disease
Researchers at Ohio State University have developed a new gene therapy that makes use of exosomes, fluid sacs released in cells, to carry therapeutic tools...
DEC 21, 2019
Drug Discovery & Development
DEC 21, 2019
Improving Vaccines for Meningitis
Scientists at the University of Nottingham are seeking new ways to improve vaccine use in the protection against the bacterium, Neisseria meningitides that...
JAN 15, 2020
Cancer
JAN 15, 2020
Hope for patients with AML
Research published recently in the medical journal EMBO Molecular Medicine brings hope for leukemia patients with a report that a common and cheap drug may...
JAN 21, 2020
Cannabis Sciences
JAN 21, 2020
Medical Marijuana Ineffective for Long Term Pain Management
Medicinal cannabis may not as effective as once thought as a solution for sleep problems for those with chronic pain in the long run, according to new find...
JAN 18, 2020
Drug Discovery & Development
JAN 18, 2020
Using Vitamins to Treat Pediatric Sepsis
New research indicates that is very much possible to treat pediatric septic shock in children with a combination of intravenous vitamin C and intravenous v...
Loading Comments...